Lipid and endothelium-related genes, ambient particulate matter, and heart rate variability - The VA Normative Aging Study

Journal of Epidemiology and Community Health

Volumn 64, Issue 1, 2010, Pages 49-56

  Ren, C ^a   Baccarelli, A ^b   Wilker, E ^a   Suh, H ^a   Sparrow, D ^c   Vokonas, P ^c   Wright, R ^d   Schwartz, J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN LIPASE; VASCULOTROPIN;

CARDIOVASCULAR SYSTEM; GENE; LIPID; METABOLISM; PARTICULATE MATTER; POLYMORPHISM;

ADULT; AGED; AIR POLLUTION; ARTICLE; DNA POLYMORPHISM; ENDOTHELIUM; ENVIRONMENTAL EXPOSURE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART RATE VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; MALE; PARTICULATE MATTER;

AGED; AGED, 80 AND OVER; AIR POLLUTANTS; APOLIPOPROTEINS E; ENDOTHELIUM; GENOTYPE; HEART RATE; HUMANS; LIPOPROTEIN LIPASE; LONGITUDINAL STUDIES; MALE; PARTICULATE MATTER; POLYMORPHISM, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74049135288     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2008.083295     Document Type: Article

References (75)

1. Schwartz J, Morris R. Air pollution and hospital admissions for cardiovascular disease in Detroit, Michigan. Am J Epidemiol 1995;142:23-35.
2. Schwartz J. Air pollution and hospital admissions for heart disease in eight U.S. counties. Epidemiology 1999;10:17-22.
3. Samet JM, Dominici F, Curriero FC, et al. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 2000;343:1742-9.
4. Pope CA III, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002;287:1132-41.
5. Ren C, Tong S. Temperature modifies the health effects of particulate matter in Brisbane, Australia. Int J Biometeorol 2006;51:87-96.
6. Laden F, Schwartz J, Speizer FE, et al. Reduction in fine particulate air pollution and mortality - extended follow-up of the Harvard six cities study. Am J Repir Crit Care Med 2006;173:667-72.
7. Schwartz J. What are people dying of on high air pollution days? Environ Res 1994;64:26-35.
8. Peters A, Dockery D, Muller JE, et al. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001;103:2810-5.
9. Sullivan J, Sheppard L, Schreuder A, et al. Relation between short-term fine-particulate matter and onset of myocardial infarction. Epidemiology 2005;16:41-48.
10. Forastiere F, Stafoggia M, Picciotto S, et al. A Case-Crossover Analysis of Out-of-Hospital Coronary Deaths and Air Pollution in Rome, Italy. Am J Respir Crit Care Med 2005;172:1549-55.
11. Zanobetti A, Schwartz J. The effect of particulate air pollution on emergency admissions for myocardial infarction: a multi-city case-crossover analysis. Environ Health Perspect 2005;113:978-82.
12. Rich DQ, Schwartz J, Mittleman MA, et al. Association of short-term ambient air pollution concentrations and ventricular arrhythmias. Am J Epidemiol 2005;161:1123-32.
13. Rich DQ, Kim MH, Turner JR, et al. Association of ventricular arrhythmias detected by implantable cardioverter defibrillator and ambient air pollutants in the St Louis, Missouri metropolitan area. Occup Environ Med 2006;63:591-6.
14. Tsui H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events: the Framingham Heart Study. Circulation 1996;94:2850-5.
15. Bigger JT Jr, Fleiss JL, Steiman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-71.
16. Rovere DTL, Bigger JT, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-84.
17. Zuanetti G, Neilson JM, Latini R, et al. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era: the GISSI-2 results. Circulation 1996;94:432-6.
18. Baccarelli A, Gassano PA, Litonjua A, et al. Cardiac autonomic dysfunction: effects from particulate air pollution and protection by dietary methyl nutrients and metabolic polymorphisms. Circulation 2008;117:1802-9.
19. Devlin RB, Ghio AJ, Kehrl H, et al. Elderly humans exposed to concentrated air pollution particles have decreased heart rate variability. Eur Respir J2003;40(Suppl):76s-80s.
20. Gold DR, Litonjua A, Schwartz J, et al. Ambient pollution and heart rate variability. Circulation 2000;101:1267-73.
21. Pope CA III, Hansen ML, Long RW, et al. Ambient particulate air pollution, heart rate variability, and blood markers of inflammation in a panel of elderly subjects. Environ Health Perspect 2004;112:339- 45.
22. Schwartz J, Litonjua A, Suh H, et al. Traffic related pollution and heart rate variability in a panel of elderly subjects. Thorax 2005;60:455-61.
23. Brook RD, Franklin B, Cascio W, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the expert panel on population and prevention science of the American Heart Association. Circulation 2004;109:2655-71.
24. Donaldson K, Stone V, Seaton A, et al. Ambient particle inhalation and the cardiovascular system: potential mechanisms. Environ Health Perspect 2001;109(Suppl 4):523-7.
25. Utell MJ, Frampton MW. Cardiovascular effects associated with air pollution: potential mechanisms and methods of testing. Inhal Toxicol 2002;14:1231-47.
26. Eller NH, Malmberg B, Bruhn P. Heart rate variability and intima media thickness. Int J Behav Med 2006;13:201-13.
27. Gottsäter A, Ahlgren AR, Taimour S, et al. Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes. Clin Auton Res 2006;16:228-34.
28. Huikuri HV, Jokinen V, Syvänne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1999;19:1979-85.
29. Nagata K, Sasaki E, Goda K, et al. Differences in heart rate variability in nonhypertensive diabetic patients correlate with the presence of underlying cerebrovascular disease. Clin Physiol Funct Imaging 2006;26:92-8.
30. Sajadieh A, Nielsen OW, Rasmussen V, et al. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004;25:363-70.
31. Sloan RP, McCreath H, Tracey KJ, et al. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 2007;13:178-84.
32. Suwa T, Hogg JC, Quinlan KB, et al. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002;39:935-42.
33. Malcom GT, McMahan CA, McGill HC, et al. Associations of arterial tissue lipids with coronary heart disease risk factors in young people. Atherosclerosis 2008;203:515-21.
34. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it-almost. J Lipid Res 2006;47:1-14.
35. Bennet AM, Angelantonio ED, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-11.
36. Bersano A, Ballabio E, Bresolin N, et al. Genetic polymorphisms for the study of multifactorial stroke. Hum Mutat 2008;29:776-95.
37. Noh H, Yamashita H, Goldberg IJ. Cardiac metabolism and mechanics are altered by genetic loss of lipoprotein triglyceride lipolysis. Cardiovasc Drugs Ther 2006;20:441-4.
38. Talmud PJ, Stephens JW. Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease risk. Diabetes Obes Metab 2004;6:1-7.
39. Al-Kateb H, Mirea L, Xie X, et al. Multiple variants in vascular endothelia growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes 2007;56:2161-8.
40. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:3611-16.
41. Howell WM, Ali S, Rose-Zerilli MJ, et al. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 2005;42:485-90.
42. Bell B, Rose C, Damon A. The normative aging study: an interdisciplinary and longitudinal study of health and aging. Aging Human Develop 1972;3:4-17.
43. Park SK, O'Neill MS, Vokonas PS, et al. Effects of air pollution on heart rate variability: the VA Normative Aging Study. Environ Health Perspect 2005;113:304-9.
44. Sun X, Ding H, Hung K, et al. A new MALDI-TOF based mini-sequencing assay for genotyping of SNPS. Nucleic Acids Research 2000;28:e68.
45. Lee LG, Connell CR, Bloch W. Allelic discrimination by nick-translation PCR with luorogenic probes. Nucleic Acids Res 1993;21:3761-6.
46. Schwartz J, Park SK, O'Neill MS, et al. Glutathione-S-transferase M1, obesity, statins, and autonomic effects of particles. Am J Respir Crit Care Med 2005;172:1529-33.
47. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006;31:445-54.
48. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-biding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982;257:2518-21.
49. Eichner JE, Dunn ST, Perveen G, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-95.
50. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
51. Utermann G, Langenbeck U, Beisiegel U, et al. Genetics of the apolipoprotein E system in man. Am J Hum Genet 1980;32:339-47.
52. Andreotti G, Chen J, Gao Y, et al. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2008;17:525-34.
53. Paternoster L, González NAM, Lewis S, et al. Association between apolipoprotein E genotype and carotid intima-media thickness may suggest a specific effect on large artery atherothrombotic stroke. Stroke 2008;39:48-54.
54. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insight into plaque formation and destabilization. Stroke 2006;37:1923-32.
55. Tikellis C, Jandeleit-Dahm KA, Sheehy K, et al. Reduced plaque formation induced by rosglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis 2008;199:55-64.
56. Chappell DA, Inoue I, Fry GL, et al. Cellular catabolism of normal very low density lipoproteins via the low density lipoprotein receptor-related protein/a2-macroglobulin receptor is induced by the C-terminal domain of lipoprotein lipase. J Biol Chem 1994;269:18001-6.
57. Zheng C, Murdoch SJ, Brunzell JD, et al. Lipoprotein Lipase Bound to Apolipoprotein B Lipoproteins Accelerates Clearance of Postprandial Lipoproteins in Humans. Arterioscler Thromb Vasc Biol 2006;26:891-6.
58. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation 1999;99:2901-7.
59. Mailly F, Tugrul Y, Reymer PW, et al. A common variant in the gene for lipoprotein lipase (Asp9->Asn): Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1995;15:468-78.
60. Reymer PW, Gagne E, Groenemeyer BE, et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995;10:28-34.
61. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997;135:145-59.
62. Hu Y, Liu W, Huang R, et al. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases. J Lipid Res 2006;47:1908-1914.
63. Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006;26:1236-45.
64. Talmud PJ, Bujac SR, Hall S, et al. Substitution of asparagines for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers. Atherosclerosis 2000;149:75-81.
65. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
66. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-44.
67. Leung DW, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
68. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
69. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9.
70. Chahine T, Baccarelli A, Litonjua A, et al. Particulate air pollution, Oxidative stress genes, and heart rate variability in an elderly cohort. Environ Health Perspect 2007;115:1617-22.
71. Park SK, O'Neill MS, Wright RO, et al. HFE genotype, particulate air pollution, and heart rate variability: a gene-environment interaction. Circulation 2006;114:2798-805.
72. Wright RO, Hu H, Silverman EK, et al. Apolipoprotein E genetype predicts 24-month Bayley scales infant development score. Pediatr Res 2003;54:819-25.
73. Puttonen S, Elovainio M, Kivimäki M, et al. The combined effects of apolipoprotein E polymorphism and low-density lipoprotein cholesterol on cognitive performance in young adults. Neuropsychobiology 2003;48:35-40.
74. Oriá RB, Patrick PD, Zhang H, et al. APOE 4 protects the cognitive development in children with heavy diarrhea burdens in northeast Brazil. Pediatr Res 2005;57:310-16.
75. Sarnat JA, Brown KW, Schwartz J, et al. ambient gas concentrations and personal particulate matter exposures: implications for studying the health effects of particles. Epidemiology 2005;16:385-95.